Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel by Kantelhardt, Eva J et al.
STUDY PROTOCOL Open Access
Prospective evaluation of prognostic factors
uPA/PAI-1 in node-negative breast cancer: Phase
III NNBC3-Europe trial (AGO, GBG, EORTC-PBG)
comparing 6 × FEC versus 3 × FEC/3 × Docetaxel
Eva J Kantelhardt
1*, Martina Vetter
1, Marcus Schmidt
2, Corinne Veyret
3, Doris Augustin
4, Volker Hanf
5,
Christoph Meisner
6, Daniela Paepke
7, Manfred Schmitt
7, Fred Sweep
8, Gunter von Minckwitz
9,
Pierre-Marie Martin
10, Fritz Jaenicke
11, Christoph Thomssen
1 and Nadia Harbeck
12
Abstract
Background: Today, more than 70% of patients with primary node-negative breast cancer are cured by local
therapy alone. Many patients receive overtreatment by adjuvant chemotherapy due to inadequate risk assessment.
So far, few clinical trials have prospectively evaluated tumor biology based prognostic factors. Risk assessment by a
biological algorithm including invasion factors urokinase-type plasminogen activator (uPA) and its inhibitor
plasminogen activator inhibitor type 1 (PAI-1) will assess up to 35-55% of node-negative patients as low-risk and
thus avoid chemotherapy. In contrast, a clinical-pathological algorithm will only classify 20-40% of patients as low-
risk. High-risk node-negative patients should receive chemotherapy. Anthracycline-based regimens are accepted as
a standard, the additional benefit of taxanes remains an open question.
Methods/Design: The international NNBC3 ("Node Negative Breast Cancer 3-Europe”) trial compares biological risk
assessment (UP) using invasion factors uPA/PAI-1 with a clinical-pathological algorithm (CP). In this trial, the type of
risk assessment (CP or UP) was chosen upfront by each center for its patients. Fresh frozen tissue was obtained to
determine uPA/PAI-1 using an enzyme-linked immunosorbent assay (ELISA). Patients assessed as high-risk were
stratified by human epidermal growth factor receptor 2 (HER2) status and then randomised to receive
anthracycline-containing chemotherapy 5-Fluorouracil (F)/Epirubicin (E)/Cyclophosphymide (C) or an anthracycline-
taxane sequence (FE100C*6 versus FE100C*3 followed by Docetaxel100*3).
Discussion: In this trial, 4,149 node-negative patients with operable breast cancer from 153 centers in Germany
and France were included since 2002. Measurement of uPA/PAI-1 by ELISA was performed with standardised
central quality assurance for 2,497 patients (60%) from 56 “UP"-centers. The NNBC 3-Europe trial showed that
inclusion of patients into a clinical phase III trial is feasible based on biological testing of fresh frozen tumor
material. In addition, 2,661 patients were classified as high-risk and thus received chemotherapy. As adjuvant
chemotherapy, 1,334 high-risk patients received FE100C-Docetaxel100, and 1,327 received French FE100C. No
unexpected toxicities were observed. Chemotherapy efficacy and comparison of UP with CP will be evaluated after
longer follow-up.
Trial Registration: clinical Trials.gov NCT01222052.
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Breast Cancer in Germany
In Germany, about 58,000 patients are newly diagnosed
with breast cancer every year. Today, approximately 80%
of patients can expect to be cured or to experience at
least long-term survival of more than 10 years. Due to
the activities of the national screening program, a grow-
ing number of early tumors are detected. Most patients
have no or only a few (1-3) axillary lymph nodes
involved and therefore have a good chance of being
cured. Thus, overtreatment is increasingly becoming an
issue.
One of the major clinical questions is how to identify
t h o s ep a t i e n t sw h om a yb ea b l et oa v o i da d j u v a n tc h e -
motherapy because of their low risk of recurrence. Bet-
ter prognostic factors are urgently needed to predict the
individual risk of recurrence.
Yet, patients with node-negative disease at high risk of
recurrence should receive adjuvant chemotherapy. How-
ever, the most effective type of chemotherapy regimen is
uncertain. In order to avoid unnecessary side-effects,
prospective, randomised controlled comparisons of regi-
mens with and without taxanes are needed.
Prognostic factors in node-negative breast cancer
Clinical and pathological assessment
Most clinicians use grade of differentiation, age, tumor
size, steroid hormone receptor status, HER2 expression
and sometimes proliferation markers (e.g. Ki-67 or gene
signatures like OncotypeDX™) in order to decide which
patient with node-negative disease should receive adju-
vant chemotherapy. In case of undifferentiated cancers
(grade 3), patients are truly at high-risk and may benefit
from chemotherapy, whereas in case of well-differen-
tiated grade 1 cancers, the risk of recurrence may be
rather low. However, in the heterogeneous group of
grade 2 tumors, it is essential to know for which
patients the benefits of chemotherapy will outweigh its
potential side effects. The widely used clinical-pathologi-
cal risk evaluation was defined at the consensus meet-
ings of St. Gallen [1].
uPA/PAI-1 for risk evaluation
There is an increasing focus on new biological factors to
further assess risk of recurrence in patients with grade 2
breast cancers in order to avoid unnecessary chemotherapy.
The “uPA/PAI-1-algorithm” gives promising results [2-4].
The capacity of breast cancer for invasion and early
hematogenic metastasis is closely related to the action
of receptor-bound, tumor-associated proteases and a
central role of the serine protease uPA (urokinase-type
plasminogen activator). In independent studies, several
groups have shown that the uPA antigen content in
tumor tissue is a strong and independent prognostic fac-
tor in primary breast cancer [5]. Particularly within the
node-negative group, the relative risk of relapse and
decreased survival was highest in patients with elevated
uPA-levels. In addition, the plasminogen activator inhi-
bitor-type 1 (PAI-1) content in tumour tissue is also
related to an increased risk of relapse and decreased
survival which becomes visible by PAI-1 being a strong
and independent prognostic factor in multivariate analy-
sis. Combining the two invasion factors, uPA and PAI-1,
by sequential selection (regression tree analysis) in
node-negative breast cancer patients, a high-risk group
can be identified comprising about 45% of all node-
negative patients. Moreover, the remaining 55% of
node-negative patients have an extremely low risk of
relapse (93% disease-free survival after 3 years without
any adjuvant therapy), so that adjuvant chemotherapy
does not seem to be indicated [5,6,2].
In the first prospective, randomized, multicenter trial
(Chemo N0), these retrospective data were validated and
confirmed [3,7]. In long-term follow-up (10 years), uPA/
PAI-1 and tumor grade remained the only independent
prognostic factors with a hazard ratio of 3.2 and 2.8,
respectively [8].
The Chemo N0 trial demonstrated that determination
of uPA and PAI-1 in tumor tissue by ELISA is easily
feasible in every laboratory. The international, quality-
control system for uPA/PAI-1 determination showed
only non-relevant inter-laboratory variations (CV 10-
15%) [9]. The clinically most important conclusion from
the Chemo N0 data is that at least 44% of all node-
negative patients could potentially be spared from adju-
vant chemotherapy. Patients with high levels of uPA
and/or PAI-1 are at high risk for relapse and should
therefore receive optimal adjuvant chemotherapy [10,8]
A pooled analysis by the European Organisation for
Research and Treatment of Cancer Receptor and Bio-
marker Group (EORTC-RBG) used the raw data of
most uPA and PAI-1 determinations available at the
time worldwide in numerous retrospective and prospec-
tive breast cancer studies and confirmed the prognostic
value in more than 8,000 patients [2,11,12]. These new
prognostic factors, uPA/PAI-1, thus conform to the
requirements for clinical acceptance put forward by the
late W McGuire and GM Clark in the early nineties
[13]. The American Society of Clinical Oncology
(ASCO) also added uPA/PAI-1 to the list of recom-
mended prognostic tumor markers for breast cancer
[14]. The recommendations for diagnosis and treatment
of breast cancer issued by the “Kommission Mamma
der Arbeitsgemeinschaft Gynäkologische Onkologie
(AGO) e. V. in der Deutschen Gesellschaft für Gynäko-
logie und Geburtshilfe e. V. sowie in der Deutschen
Krebsgesellschaft e. V. “ have even supported the use of
uPA/PAI-1 in node-negative breast cancer already since
2002 [15].
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The current ASCO guidelines also recommend the use
of the 21-Gene assay. This test is available for paraffin
embedded tissue. It is based on a reverse transcriptase
polymerase chain reaction (RT-PCR) determination of
the mRNA expression of 16 tumor-specific genes and 5
control genes. It is widely used in the USA for node-
negative or node-positive (1-3 lymph nodes), hormone-
receptor positive patients. A high recurrence score is
associated with a high probability of recurrence and
benefit from adjuvant chemotherapy. This commercially
available test (OnkotypeDX™) is currently evaluated in
a prospective randomised trial (Trial Assigning Indivi-
duaLized Options for Treatment (Rx), TAILORx) com-
paring clinical-pathological versus biological risk
assessment by the 21-Gene assay. First results of
>10,000 patients are expected at the end of the trial in
2014 [16]. In Germany, the prospective WSG Plan B
trial evaluating efficacy of anthracycline-free chemother-
apy in primary HER2-negative breast cancer after mole-
cular-based risk assessment according to Oncotype DX
and uPA/PAI-1 has already recruited almost 2,500 pri-
mary breast cancer patients by early 2011[17].
An additional test, the 70-gene array, is also based on
genetic profiling of the tumor. MRNA is prepared from
fresh tissue of node-negative and node-positive (1-3
lymph nodes) breast cancer and analyzed by a multi-
gene expression-array. This signature is also able to pre-
dict an individual patient’s risk of recurrence and survi-
val (low vs. high). This commercially available test
(MammaPrint™) is currently being evaluated in a pro-
spective randomized trial comparing clinical-pathologi-
cal versus biological risk assessment. The Microarray In
Node-negative and 1 to 3 positive lymph node Disease
may Avoid ChemoTherapy (MINDACT) trial started
2006 and will recruit 6,000 patients [18].
Another commercially available gene array to predict
the individual risk of recurrence is the 76-gene signature
(Rotterdam signature, Affymetrix™) [19]. In addition,
the HOXB13:IL17BR ratio index give prognostic infor-
mation for ER positive tumors and the molecular grade
index (five genes) (H/I
SM and MGI
SM by Biotheranos-
tics™, France) [20,21].
Many promising preclinical results have been pub-
lished for biomarkers giving not only prognostic infor-
mation but also predicting therapeutic response and
monitoring therapeutic interventions. Information may
be derived from the tumor or other patient specimens
as mRNA but also DNA, DNA-methylation status, his-
tone markers and miRNA [22].
Molecular “intrinsic” typing
Biologically meaningful breast-cancer tumor types have
been derived from expression array analyses [23,24]. This
molecular typing defines luminal (ER-positive), HER2-
type (HER2 overexpressing) and basal-like (often ER and
PR and HER2-negative, so called triple-negative) breast
cancers, and thus tumor types that respond to specific
therapies such as endocrine therapy for luminal and anti-
HER2 agents for HER2 type cancers. Luminal breast can-
cers can be further divided into low-risk (luminal A) and
high-risk (luminal B) tumors. Luminal B tumors are
highly proliferating [25] and should be treated with che-
motherapy in addition to the endocrine therapy. Efforts
have been made to substitute gene-expression profiling
(requiring frozen tissue) by immunohistochemical analy-
sis of formalin fixed specimen. Since the results of these
two techniques do not correlate well so far, their results
should still be used with care.
Treatment of patients with node-negative breast cancer
In 2005, the Early Breast Cancer Trialists’ Collaborative
Group (EBCTCG) showed that anthracycline-containing
regimens account for up to a 38% (postmenopausal) and
20% (premenopausal) relative reduction in the cumulative
15-year mortality in addition to that attributable to endo-
crine therapy [26]. Several anthracycline-containing regi-
mens are currently used [15] and so far there is no direct
comparison supporting superiority of an individual regi-
men provided that an adequate dose is used. The EORTC
Breast Cancer Group used two different anthracycline-
containing regimens as standard in their neo-adjuvant che-
motherapy trials. Study 10921 (closed 1996) used Canadian
FE120C [27]. Analysis of the dose-intensity data, however,
demonstrated that the median dose-intensity delivered for
epirubicin was 100 mg/m² for the standard arm because of
toxicity leading to early dose adjustment [28]. Conse-
quently, the EORTC trial 10994 (p53 study) used the
FE100C regimen as its standard [29] - it also seems to be a
feasible standard in the adjuvant setting [30,15].
A recent meta-analysis demonstrated that Taxanes
(docetaxel (T), paclitaxel (Pac)) are very active agents in
the adjuvant treatment of all breast cancer patient sub-
groups [31]. There was one major trial particularly com-
paring a taxane-containing regimen with a solely
anthracycline-based regimen in node-negative breast
cancer: The GEICAM 9805 trial recruited 1,059 high-
risk, node-negative, breast-cancer patients. Docetaxe-
lA50C*6 (TAC) was compared to FA50C*6. The taxane
arm was significantly superior regarding disease-free
survival (DSF) (hazard ratio (HR) 67%). Overall survival
(OS) showed a non-significant trend (HR 0.70) favoring
TAC. As expected, side effects were more frequent in
the taxane-containing arm [32]. Recently, Docetaxel has
also been approved in Europe for treatment of node-
negative breast cancer.
The CALGB #9344 trial compared 4 courses of stan-
dard AC with a sequence of 4x AC followed by 4 courses
of Pac in 3,000 node-positive patients. Patients treated
by AC⇒Pac had significantly fewer recurrences [33].
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in the AC⇒Pac arm were on therapy twice as long as
those in the control arm; the beneficial chemotherapy
effect may thus be merely attributable to a longer dura-
tion of chemotherapy. In addition, retrospective sub-
group analyses of this trial showed that the significant
advantage of adding paclitaxel was only present in
patients with steroid hormone receptor-negative tumors.
Consequently, in the NNBC 3-Europe trial, a balanced
comparison between an anthracycline-containing
(FE100C) and a sequential anthracycline-taxane (FE100C-
Docetaxel sequence) therapy was chosen with identical
dose-intensity and chemotherapy duration in both trial
arms. For the taxane-containing sequence, safety data
and efficacy data for node-positive disease were already
available [34].
Aim of the NNBC 3-Europe trial
The NNBC 3-Europe trial was aimed to compare biolo-
gical with clinical-pathological risk assessment in
patients with newly-diagnosed node-negative breast can-
cer. In addition, the question should be answered
whether high-risk node-negative patients should receive
adjuvant chemotherapy with or without taxanes.
Methods/Design
Design of the NNBC 3-Europe trial
Overall design
In this international, multicenter, prospectively-rando-
mized, controlled trial, 4,149 node-negative patients
with operable breast cancer were included. Risk of
recurrence was assessed either by a clinical-pathological
(CP) or by a biological algorithm based on uPA/PAI-1
(UP). Type of risk assessment (CP or UP) was decided
up-front by each center for all of its patients and then
used as a stratification parameter for the trial. Patients
assessed as high-risk were stratified by HER2 status and
then randomized to receive anthracycline-containing
(FE100C*6) or anthracycline and taxane-containing
(FE100C*3 followed by Docetaxel100*3) chemotherapy.
A difference regarding disease-free survival between
the two chemotherapy arms is expected. Moreover, dis-
cordance/concordance between the two methods of
prognostic assessment will be compared concerning pro-
portion and DFS of low-risk patients in each of the two
risk assessment groups.
The benefit of anthracycline/taxane-containing che-
motherapy compared to solely anthracyline-containing
chemotherapy will also be evaluated in HER2 positive
patients.Trial objectives:
￿ Comparison of the chemotherapy regimes
￿ Comparison of clinical-pathological vs. biological
(uPA/PAI-1) risk assessment
￿ Comparison of the chemotherapy regimes in HER2
over-expressing breast cancer
Ethical approval was obtained by the institutional
review board of the principle investigator as well as of
each participating center.
Patients
Patients age 18-65 were eligible for the trial if they had a
histological proven primary breast cancer (0.5-5 cm,
pN0, M0, R0). For centers using biological risk assess-
ment, frozen tissue had to be available from all patients
for uPA/PAI-1 testing. Patients needed to be of ade-
quate health in order to undergo the recommended
chemotherapy.
Procedures
After informed consent, patients were registered for the
trial (figure 1). In “biological” centers working with UP,
frozen tissue was sent to designated laboratories for
uPA/PAI-1determination. After confirmation of node-
negative disease, patients were classified by their risk
status as assessed by either clinical-pathological criteria,
or by biological criteria (Classification 1). Patients found
to be low-risk according to either CP or UP (see below)
were observed; patients found to be high-risk either by
CP or UP received adjuvant chemotherapy within the
trial (Classification 2). A stratification step was per-
formed according to HER2 status (Stratification). All
high-risk patients were randomly assigned to one of the
Patients with node-negative breast cancer
(NNBC); tumour size 0.5–5 cm; age 18–65 yrs
Selection by tumour-
biological factors
uPA and PAI-1 
Selection by
clinico-pathological
factors
FE100C*6 FE100C*3Æ Æ Æ ÆDoc*3
S: stratification by HER-2/neu expression
C1: type of risk assessment
R
Endocrine treatment if Pg.-positive accorording to the latest standard recommendations of the AGO
Sample tumour tissue+
observation
C2: high risk vs low risk
low risk high risk
Figure 1 Design of the NNBC 3-Europe trial. Stratification and
randomization schedule: C1 = stratification by type of risk
assessment based on choice of the centre (type of risk assessment);
C2 = stratification by risk status; S = Stratification by HER-2/neu-FISH
result; R = randomisation (FE100C: 5-Fluorouracil 500 mg/m²,
Epirubicin 100 mg/m², Cyclophosphamide 500 mg/m², q3 wks; Doc:
Docetaxel 100 mg/m², q3 wks.). += fresh tumour tissue for patients
within the “biological UP pathway”, additionally in all patients
paraffin blocks for central review.
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Docetaxel) (Randomization). All patients received breast
radiotherapy if breast conserving surgery had been per-
formed. Radiotherapy, endocrine therapy, and trastuzumab
were given according to current AGO recommendations
at the time (http://www.ago-online.org).
Risk Assessment
The gold standard to prospectively compare risk
assessment procedures would have been randomisa-
tion of each patient to either CP or UP risk assess-
ment. To avoid reduced accrual because of physicians’
bias or patients not accepting such a rather compli-
cated procedure, consistent risk assessment within
each center was chosen as a clinically feasible proce-
dure for the trial. Moreover, not all centers were logis-
t i c a l l ya b l et oa s c e r t a i nf r esh frozen tissue for UP.
Thus, randomization of the centers for method of risk
assessment was not feasible. Accounting for individual
conditions and preferences, each centre was therefore
allowed to select the method of risk assessment for all
of their patients.
Risk assessment by clinical and pathological factors (CP)
The integrated clinical-pathological algorithm used to
select high-risk patients was derived from the St. Gallen
recommendations and the Nottingham Prognostic Index
(NPI) system Centers using CP classified all patients
younger than 35 years or with a G3 tumor, or with a
HER2 positive tumor or with progesterone receptor-
negativity or vascular invasion as high-risk. In addition,
patients with G2 tumors were considered high-risk if
their tumor was ≥2 cm (figure 2).
Risk assessment by biological factors (UP)
Centers using biological criteria classified all patients
with G3 tumors or <35 years as high-risk, and all
patients with G1 tumors as low-risk. Invasion factors
uPA/PAI-1 were determined in all G2 tumors. If either
factor was above the pre-defined cut-off, the patient was
classified as high-risk. The other clinical and pathologi-
cal factors did not influence biological risk assessment
(Figure 3).
Laboratory procedures
Tissue sampling for biological risk assessment (UP) was
done either by excisional or by core-needle biopsy
(3 biopsies sent). Core-needle biopsy material has been
shown to allow reliable uPA/PAI-1 determination [35].
Regarding excisional biopsies, the pathologist confirmed
the diagnosis of breast cancer, excised a representative
piece of the tumor (optimum 100-300 mg) and snap-
froze it immediately in liquid nitrogen.
The centers received UP results within a maximum
duration of 10 days.
In the trial, uPA and PAI-1 concentrations were mea-
sured in non-ionic, detergent-released, tumor-tissue
extracts (Triton X-100) using the FEMTELLE
® ELISA
kit #899 by American Diagnostica (cut-off values had
been previously validated for this kit [36]). Total protein
measurements were performed by the Bicinchoninic
acid (BCA) test (Pierce #23225). Tissue handling and
methods of measurement have been extensively
described elsewhere [37]. Patients with an uPA concen-
tration of ≤3 ng/mg total protein and a PAI-1 concen-
tration of ≤14 ng/mg total protein in the Triton X-100
tissue extract of their primary tumor have a very low
Node-Negative
Breast Cancer Patients
G1 G1 G2 G2
Check for risk factors:  age<35 yrs., G3, HER2-pos.,
PgR-neg., vascular invasion
T 2cm
High risk
If any positive
(endocrine responsiveness
negative or uncertain)
If all negative
(endocrine responsive)
Low risk
T <2cm
Figure 2 Risk assessment using the clinical and pathological
algorithm (CP) adopted from St. Gallen and NPI. - all patients
G1 or G2 <2 cm were assessed as low-risk if no additional risk
factors were present. Patients showing an additional risk factor or
G2tumors ≥2 cm or G3 were assessed high-risk.
35 years
Node-Negative
Breast Cancer Patients
G1 G2
High risk Low risk
uPA and/or
PAI-1 high
uPA low &
PAI-1 low
<35 years
G3
Figure 3 Risk assessment using the uPA/PAI-1 algorithm (UP) -
all patients with G1 tumors were assessed low-risk, all patients with
G3 tumors or ≤35 years were assessed high-risk. Patients with G2
tumors were assessed high-risk if uPA and/or PAI-1 were elevated
above the validated cut-off levels.
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risk [5].
All laboratories participating in this multicenter trial
also participated in the EORTC PBG supported interna-
tional quality assurance program provided by the central
trial laboratory (FCGJ Sweep, Nijmegen, Netherlands).
The coefficient of variation showed a maximum of 12%
for both assays.
Chemotherapy
All patients received 3 cycles of FE100C every 3 weeks
consisting of 5-FU 500 mg/m2 IV, epirubicine 100 mg/
m2 IV infusion, and cyclophosphamide 500 mg/m
2 IV
infusion. Prophylactic antiemetic treatment was given
according to each center’s policy, no prophylactic anti-
biotics or prophylactic granulocyte-colony stimulating
factors (G-CSF) were allowed but secondary prophylaxis
was allowed. Patients in the FEC arm then continued
for another 3 cycles of FEC. Patients in the docetaxel
arm continued with docetaxel 100 mg/m
2 IV every 3
weeks. Oral steroids were given for 3 days. Prophylactic
G-CSF was recommended according to guidelines. Dose
modification was done for hematological or non-hema-
tological toxicity according to the protocol consistent
with standard recommendations (National Cancer
Institute).
Radiotherapy, endocrine therapy and trastuzumab
All other adjuvant treatment was given according to
current AGO recommendations [38].
Follow-up
On-site monitoring was performed once for all centers
after the last patient was included into the trial. All
high-risk and low-risk patients are followed for 5 years.
Data is entered by the local centers into an electronic
data capture system.
Statistical analyses
Endpoints were chosen as follows:
1. For the population treated by chemotherapy:
￿ Primary endpoint of the study is Disease-Free Sur-
vival (DFS)
￿ Secondary endpoints are: Overall Survival (OS) and
Safety, and
￿ side-effects of chemotherapy in each study arm
2. For the entire population of registered patients:
￿ DFS in each low-risk group (or in each patient
group stratified for type of risk selection, CP or UP,
respectively), and
￿ proportion of node-negative breast cancer patients
grouped into each low-risk group
Sample size calculation
Questions arising
1. NNBC3-Europe is a randomized, multicenter,
open-label, phase III trial designed to detect - with
adequate power - a difference in efficacy between
two chemotherapy regimens in high-risk node-nega-
tive, operable breast cancer.
2. It will also quantify the discordance/accordance of
clinical and pathological characteristics and of the bio-
logical characteristics with regard to risk assessment in
all patients. Therefore, DFS of each low-risk group and
of each patient group classified according to type of
risk selection, respectively, will be compared as well as
the proportion of node-negative breast cancer patients
grouped into that particular low-risk group.
3. To investigate whether registered patients (low-
risk patients according to their particular risk assess-
ment criterion) can still be discriminated with
respect to their risk of first recurrence and survival
if the other assessment criterion is used.
4. To investigate prospectively whether patients with
HER2 over-expression have a higher benefit by an
adjuvant anthracycline-taxane sequence than by a
solely anthracycline-based combination.
Ad question 1 - difference between chemotherapy regimens
The primary endpoint for the biometrical evaluation is
DFS.
Assuming an event rate of 13% at 5 years follow-up in
the standard FE100C arm, a difference of 4% in the event
rate is considered to be clinically relevant.
When the sample size in each group is 1,286, an expo-
nential maximum-likelihood test of equality of survival
curves with a 0.050 two-sided significance level will
have 80% power to detect the difference between a
group 1 exponential parameter of 0.0023 (equivalent to
a 13% event rate at 5 years) and a group 2 exponential
parameter of 0.0016 (equivalent to a 9% event rate at 5
years) (constant hazard ratio of 1.477).
Ad question 2 - difference between risk assessment types
The primary endpoint for the biometrical evaluation is
DFS. The power was computed for the question whether
the two types of risk assessment are equivalent regard-
ing DSF. The statistical analysis was planned under the
condition that patient allocation to one of the two types
of risk assessment is not randomized but depends on
the policy of each center (see above). Therefore, it was
expected that the two groups formed by the risk assess-
ment methods are not homogeneously distributed
regarding all relevant prognostic factors.
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exact power calculation for multivariate statistical meth-
ods with event times as the endpoint and equivalence as
the main question of the analysis. As an approximation
for the power calculation, we used the known calculation
for simple proportions as the endpoint and equivalence
as the main question. In the final analysis, multivariate
methods using DFS as the endpoint will be used.
If sample sizes in the groups are 1,900 and 3,800, a
two-group large-sample normal approximation test of
proportions with a one-sided 0.010 significance level will
have 76% power to reject the null hypothesis that the
two groups are not equivalent (the difference in propor-
tions is 0.02 or farther from zero in the same direction)
in favor of the alternative hypothesis that the propor-
tions in the two groups are equivalent, assuming that
the expected difference in proportions is 0.000 and the
overall proportion of disease-free patients is 0.959.
Closure of recruitment after entering 4,149 patients
In December 2008, the steering committee decided to
close recruitment to the trial due to several reasons:
￿ The estimated number of patients needed to
answer the chemotherapy question was definitely
reached.
￿ The answer to the second question concerning the
difference between the risk assessment groups will
probably be answered since the sample size was cal-
culated rather generously due to lack of an exact
power calculation for multivariate statistical methods
with event times as the endpoint and equivalence as
the main question of the analysis (see above).
￿ Since initially there was a rather slow inclusion of
patients, the actual recruitment fell behind the
planned recruitment and premature closure was a
predefined possibility.
Discussion
Estrogen receptor status and HER2 expression are clear
predictive factors in breast cancer indicating who will ben-
efit from endocrine and anti-HER2 therapy. No such fac-
tor has yet been found to predict response to
chemotherapy. So far, only some clinical and pathological
factors estimating prognosis have been identified. Since
chemotherapy is associated with side-effects and reduced
quality of life, the indications should be carefully decided.
Node-positive patients will most likely benefit from adju-
vant chemotherapy in a significant way. Node-negative
patients are a heterogeneous group where 70% of the
patients will be cured by loco-regional therapy alone.
Especially for patients with G2-tumours, there are no
good prognostic factors. Recently, numerous biological
tests have been suggested for risk estimation in such cases.
Only a few are currently recommended by international
guidelines (AGO, ASCO, National Comprehensive Cancer
Network). uPA/PAI-1 have been evaluated by a prospec-
tive trial showing independent prognostic value even after
10 years of follow-up (Chemo N0 trial). A meta-analysis
including more than 8,000 patients validated this indepen-
dent prognostic value. This NNBC-3 Europe trial is the
confirmatory trial regarding the prognostic value of these
factors. Moreover, the important questions of optimal che-
motherapy in high-risk node-negative patients and of
identifying node-negative patients benefitting from adju-
vant taxane-containing therapy are addressed. 4,149
patients were included and the recruitment was closed in
January 2009. First results will be available in 2011 when
142 events have been observed.
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